# ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

> **NCT03897543** · PHASE1,PHASE2 · RECRUITING · sponsor: **Abivax S.A.** · enrollment: 48 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** ABX196

## Key facts

- **NCT ID:** NCT03897543
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-30
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03897543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03897543, "ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03897543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*